title: Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
abstract: BACKGROUND
  The aim of this study was to evaluate the prognosis of the classic variant of papillary thyroid carcinomas with the BRAF(V600E) mutation and 131I treatment failure in those tumors due to lower functional sodium iodide symporter expression.
  
  
  METHODS
  109 papillary thyroid carcinomas were associated with clinicopathologic features. The BRAF(V600E) mutation was evaluated by direct sequencing and sodium iodide symporter protein was determined by immunohistochemistry.
  
  
  RESULTS
  We found that the BRAF(V600E) mutation was significantly associated with the classic variant of papillary thyroid carcinomas and was independent of tumor size, the presence of extrathyroid invasion and lymph node metastasis, advanced TMN stages, and a high risk of disease recurrence. Moreover, the BRAF(V600E) mutation was associated with a statistically significant lower functional NIS protein expression in the classic variant of papillary thyroid carcinomas. However, those statistically significant relationships were not found in the follicular variant of papillary thyroid carcinomas.
  
  
  CONCLUSIONS
  The BRAF(V600E) mutation might be associated with a more aggressive phenotype and a poor prognosis, causing less NIS-mediated 131I uptake due to a lower functional NIS protein expression in the classic variant of papillary thyroid carcinomas. Our current study appears to be valuable for predicting prognosis and is of important clinical significance for surgery and 131I treatment in patients with the classic variant of papillary thyroid carcinomas.
authors.affiliation: Huzhou Central Hospital, Zhejiang, China 313000.
authors.forename: Wei Li
authors.initials: WL
authors.lastname: Gao
authors.forename: Liu Li
authors.initials: LL
authors.lastname: Wie
authors.forename: Ye Guo
authors.initials: YG
authors.lastname: Chao
authors.forename: Lu
authors.initials: L
authors.lastname: Wie
authors.forename: Teng Li
authors.initials: TL
authors.lastname: Song
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000378:metabolism; D002277:Carcinoma / Q000235:genetics / Q000378:metabolism / Q000556:secondary* / Q000628:therapy; D002291:Carcinoma, Papillary; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D018714:Radiotherapy, Adjuvant; D027981:Symporters / Q000378:metabolism*; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000556:secondary / Q000628:therapy; D013965:Thyroidectomy; D000099209:Sodium-Iodide Symporters
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D007457:Iodine Radioisotopes; D048493:Proto-Oncogene Proteins B-raf; D027981:Symporters; D000099209:Sodium-Iodide Symporters; C482119:BRAF protein, human